Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)

The summary for the Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Early Immune System Development and Ontogeny (R01 Clinical Trial Optional): The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.

Federal Grant Title:	Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health, Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-25-362
Type of Funding:	Grant
CFDA Numbers:	93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 7th, 2029
Original Application Deadline:	January 7th, 2029
Posted Date:	December 30th, 2024
Creation Date:	December 30th, 2024
Archive Date:	February 12th, 2029
Total Program Funding:
Maximum Federal Grant Award:	$400,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	December 30th, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/pa-files/PAR-25-362.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Rehabilitation Research Career Development Programs (K12 Clinical Trial Optional); • Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - ...; • Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - ...; • Contraceptive Development Research Centers (P50 Clinical Trial Optional); • Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clin...; • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...; • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...; • Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health: • Environmental influences on Child Health Outcomes (ECHO) Cohort Data and Biospecimen Acces...; • Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed...; • Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiate...; • Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiate...; • National Alzheimers Coordinating Center (U24 Clinical Trial Not Allowed)